首页> 外文OA文献 >GLACIER: An open-label, randomized, multicenter study to assess the safety and tolerability of glatiramer acetate 40mg three-times weekly versus 20mg daily in patients with relapsing-remitting multiple sclerosis

【2h】

GLACIER: An open-label, randomized, multicenter study to assess the safety and tolerability of glatiramer acetate 40mg three-times weekly versus 20mg daily in patients with relapsing-remitting multiple sclerosis

机译：冰川：开放标签，随机的多中心研究，以评估Glatiramer醋酸盐的安全性和可耐受性，每天每周3次每周30mg对20毫克，复发延迟多发性硬化症

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Jerry S. Wolinsky; T. Erik Borresen; Dennis W Dietrich; Daniel Wynn; Yulia Sidi; Joshua R. Steinerman; Volker Knappertz; Scott Kolodny;
展开▼
作者单位

展开▼
年度 2015
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献

1. Efficacy and Safety of a Three-times Weekly Dosing Regimen of Glatiramer Acetate in Relapsing-Remitting Multiple Sclerosis Patients: 3-Year Results of the Glatiramer Acetate Low-Frequency Administration (GALA) Open-Label Extension Study. [J] . Kolodny S., Khan O., Rieckmann P., Multiple sclerosis: clinical and laboratory research . 2016,第3期

机译：醋酸格拉替雷在复发-缓解型多发性硬化症患者中每周三次给药方案的疗效和安全性：醋酸格拉替雷低频管理（GALA）开放标签扩展研究的3年结果。
2. Patient Experience with Glatiramer Acetate 40 mg/mL Three-Times Weekly Treatment for Relapsing-Remitting Multiple Sclerosis: Results from the GLACIER Extension Study. [J] . Kolodny S., Wynn D., Rubinchick S., Multiple sclerosis: clinical and laboratory research . 2016,第3期

机译：醋酸格拉替雷酯40 mg / mL每周治疗三次，用于复发缓解型多发性硬化症的患者经验：GLACIER扩展研究的结果。
3. Efficacy and safety of a three-times-weekly dosing regimen of glatiramer acetate in relapsing-remitting multiple sclerosis patients: 3-year results of the Glatiramer Acetate Low-Frequency Administration open-label extension study [J] . Khan Omar, Rieckmann Peter, Boyko Alexey, Multiple sclerosis: clinical and laboratory research . 2017,第6期

机译：三次每周给药方案的疗效和安全性醋酸三次醋酸多发性硬化症患者的疗效和安全性：Glatamer乙酸盐低频管理的3年结果开放标签扩展研究
4. Tolerability and Safety Profile of a New Brand-Generic Product of Glatiramer Acetate in Iranian Patients with Relapsing-Remitting Multiple Sclerosis: An Observational Cohort Study [O] . Roya Abolfazli, Shirin Pournourmohammadi, Ahmadreza Shamshiri, 2018

机译：醋酸格拉替雷新品牌通用产品在患有复发缓解型多发性硬化症的伊朗患者中的耐受性和安全性概况：一项观察性队列研究
5. The results of two multicenter, open-label studies assessing efficacy, tolerability and safety of protiramer, a high molecular weight synthetic copolymeric mixture, in patients with relapsing-remitting multiple sclerosis. [O] . N. D. Stefano, M. Filippi, C. Confavreux, 2009

机译：两项多中心，开放标签研究的结果，评估了高分子量合成共聚物混合物protiramer在复发缓解型多发性硬化症患者中的功效，耐受性和安全性。

GLACIER: An open-label, randomized, multicenter study to assess the safety and tolerability of glatiramer acetate 40mg three-times weekly versus 20mg daily in patients with relapsing-remitting multiple sclerosis

著录项

引文网络

相似文献

相关主题

期刊订阅